LT2938328T - Monolitinė farmacinė forma, skirta modifikuotam aktyviųjų sudedamųjų dalių derinio atpalaidavimui - Google Patents

Monolitinė farmacinė forma, skirta modifikuotam aktyviųjų sudedamųjų dalių derinio atpalaidavimui

Info

Publication number
LT2938328T
LT2938328T LTEPPCT/EP2013/077939T LTEP2013077939T LT2938328T LT 2938328 T LT2938328 T LT 2938328T LT EP2013077939 T LTEP2013077939 T LT EP2013077939T LT 2938328 T LT2938328 T LT 2938328T
Authority
LT
Lithuania
Prior art keywords
active ingredient
modified release
pharmaceutical form
ingredient combination
monolithic pharmaceutical
Prior art date
Application number
LTEPPCT/EP2013/077939T
Other languages
English (en)
Inventor
Francas GERNOT
Karl-Heinz PRZYKLENK
Original Assignee
Hennig Arzneimittel Gmbh&Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201210113098 external-priority patent/DE102012113098A1/de
Application filed by Hennig Arzneimittel Gmbh&Co. Kg filed Critical Hennig Arzneimittel Gmbh&Co. Kg
Publication of LT2938328T publication Critical patent/LT2938328T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/EP2013/077939T 2012-12-27 2013-12-23 Monolitinė farmacinė forma, skirta modifikuotam aktyviųjų sudedamųjų dalių derinio atpalaidavimui LT2938328T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE201210113098 DE102012113098A1 (de) 2012-12-27 2012-12-27 Monolithische Arzneiform zur modifizierten Freisetzung einer Wirkstoffkombination
DE102013101049 2013-02-01
PCT/EP2013/077939 WO2014102253A1 (de) 2012-12-27 2013-12-23 Monolithische arzneiform zur modifizierten freisetzung einer wirkstoffkombination

Publications (1)

Publication Number Publication Date
LT2938328T true LT2938328T (lt) 2023-11-27

Family

ID=49911528

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2013/077939T LT2938328T (lt) 2012-12-27 2013-12-23 Monolitinė farmacinė forma, skirta modifikuotam aktyviųjų sudedamųjų dalių derinio atpalaidavimui

Country Status (19)

Country Link
US (1) US20150343067A1 (lt)
EP (1) EP2938328B1 (lt)
KR (1) KR102220130B1 (lt)
AU (1) AU2013369379B2 (lt)
BR (1) BR112015015483A8 (lt)
CA (1) CA2895609C (lt)
EA (1) EA032456B1 (lt)
HU (1) HUE063546T2 (lt)
IL (1) IL239670B (lt)
LT (1) LT2938328T (lt)
MX (1) MX370067B (lt)
PH (1) PH12015501487B1 (lt)
PT (1) PT2938328T (lt)
RS (1) RS64741B1 (lt)
SA (1) SA515360671B1 (lt)
SI (1) SI2938328T1 (lt)
UA (1) UA118099C2 (lt)
WO (1) WO2014102253A1 (lt)
ZA (1) ZA201505084B (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043399T2 (hu) * 2014-06-26 2019-08-28 Hennig Arzneimittel Gmbh&Co Kg Gyógyszer, különbözõ okokból eredõ szédülés kezelésére
AU2021255701B2 (en) 2020-04-17 2025-12-04 Honeybrains, Llc Compositions and methods for treating neuropsychiatric disorders
JP2024517829A (ja) * 2021-05-05 2024-04-23 リンドラ セラピューティクス, インコーポレイティド メタドンを含む胃内滞留システム

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005014142B4 (de) * 2005-03-23 2006-11-09 Hennig Arzneimittel Gmbh & Co. Kg Pelletförmige Retardzubereitung gegen Schwindel
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
EA025128B1 (ru) * 2011-05-05 2016-11-30 Хенниг Арцнаймиттель Гмбх Унд Ко. Кг Лекарственная форма для целевого высвобождения активных веществ
DE102011075354A1 (de) * 2011-05-05 2012-11-08 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur gezielten Freigabe von Wirkstoffen

Also Published As

Publication number Publication date
PH12015501487B1 (en) 2021-03-31
HUE063546T2 (hu) 2024-01-28
IL239670B (en) 2020-08-31
PH12015501487A1 (en) 2015-09-21
EA032456B1 (ru) 2019-05-31
KR102220130B1 (ko) 2021-02-25
EP2938328A1 (de) 2015-11-04
SI2938328T1 (sl) 2023-11-30
UA118099C2 (uk) 2018-11-26
CA2895609C (en) 2021-01-12
KR20150100734A (ko) 2015-09-02
EA201500694A1 (ru) 2015-10-30
ZA201505084B (en) 2016-12-21
PT2938328T (pt) 2023-09-26
BR112015015483A8 (pt) 2019-10-22
CA2895609A1 (en) 2014-07-03
MX370067B (es) 2019-11-29
EP2938328B1 (de) 2023-07-05
IL239670A0 (en) 2015-08-31
AU2013369379A1 (en) 2015-07-16
MX2015008462A (es) 2015-09-23
WO2014102253A1 (de) 2014-07-03
BR112015015483A2 (pt) 2017-07-11
RS64741B1 (sr) 2023-11-30
AU2013369379B2 (en) 2018-03-15
US20150343067A1 (en) 2015-12-03
SA515360671B1 (ar) 2022-11-13

Similar Documents

Publication Publication Date Title
IL238713A0 (en) Self-regulating active pharmaceutical ingredient release
EP3517152C0 (en) DRUG ADMINISTRATION CONNECTORS
ZA201307862B (en) Controlled release pharmaceutical dosage forms
IN2015DN03984A (lt)
IL234363B (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
IL235000B (en) Preparations for oral administration and their use for the treatment of motor disorders
EP2836206A4 (en) PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE OF DIRECT THROMBINS
IL236465A0 (en) Pharmaceutical composition for delayed release of active substances
ZA201504520B (en) Active ingredient microparticles
IL236466B (en) Pharmaceutical composition for the release of active components
IL224495B (en) Pharmaceutical composition for the prolonged release of trimetazidine
SI2938328T1 (sl) Monolitna farmacevtska oblika za prirejeno sproščanje kombinacije učinkovin
PL2585445T3 (pl) Polimorfy aktywnego składnika farmaceutycznego
IL227651A0 (en) Pharmaceutical formulations for local introduction containing 220b
PT2704698T (pt) Forma farmacêutica para a libertação controlada de princípios activos
PL2474529T3 (pl) Formy krystaliczne farmaceutycznej substancji czynnej
HU1000444D0 (en) Process for the preparation of a pharmaceutical active ingredient
AP2014007760A0 (en) Stabilized pharmaceutical formulations of a potentHCV inhibitor
TH1401007646A (th) รูปแบบยาเวชภัณฑ์สำหรับการปลดปล่อยส่วนประกอบออกฤทธิ์ (Medicament form for release of active ingredients)